Showing 1 - 5 results of 5 for search 'Sunisa Prasopporn', query time: 0.03s Refine Results
  1. 1
    A novel bicyclic 2,4-diaminopyrimidine inhibitor of Streptococcus suis dihydrofolate reductase

    A novel bicyclic 2,4-diaminopyrimidine inhibitor of Streptococcus suis dihydrofolate reductase by Warangkhana Songsungthong, Sunisa Prasopporn, Louise Bohan, Potjanee Srimanote, Ubolsree Leartsakulpanich, Suganya Yongkiettrakul

    Published 2021-02-01
    Get full text
    Article
  2. 2
    BAIAP2L1 enables cancer cell migration and facilitates phospho‐Cofilin asymmetry localization in the border cells

    BAIAP2L1 enables cancer cell migration and facilitates phospho‐Cofilin asymmetry localization in the border cells by Nut Pipatpanyanugoon, Nicha Wareesawetsuwan, Sunisa Prasopporn, Wannapan Poolex, Trairak Pisitkun, Worasak Kaewkong, Somponnat Sampattavanich, Siwanon Jirawatnotai

    Published 2022-01-01
    Get full text
    Article
  3. 3
    Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

    Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma by Sunisa Prasopporn, Sunisa Prasopporn, Orawan Suppramote, Orawan Suppramote, Ben Ponvilawan, Chanette Jamyuang, Jantappapa Chanthercrob, Amphun Chaiboonchoe, Pimkanya More-Krong, Kamonchanok Kongsri, Monthira Suntiparpluacha, Rawisak Chanwat, Krittiya Korphaisarn, Seiji Okada, Somponnat Sampattavanich, Somponnat Sampattavanich, Siwanon Jirawatnotai, Siwanon Jirawatnotai

    Published 2022-11-01
    Get full text
    Article
  4. 4
    Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

    Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma by Sunisa Prasopporn, Sunisa Prasopporn, Orawan Suppramote, Orawan Suppramote, Ben Ponvilawan, Chanette Jamyuang, Jantappapa Chanthercrob, Amphun Chaiboonchoe, Pimkanya More-Krong, Kamonchanok Kongsri, Monthira Suntiparpluacha, Rawisak Chanwat, Krittiya Korphaisarn, Seiji Okada, Somponnat Sampattavanich, Somponnat Sampattavanich, Siwanon Jirawatnotai, Siwanon Jirawatnotai

    Published 2023-01-01
    Get full text
    Article
  5. 5
    The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma

    The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma by Orawan Suppramote, Orawan Suppramote, Sunisa Prasopporn, Satinee Aroonpruksakul, Ben Ponvilawan, Jiradej Makjaroen, Monthira Suntiparpluacha, Krittiya Korphaisarn, Komgrid Charngkaew, Rawisak Chanwat, Trairak Pisitkun, Seiji Okada, Somponnat Sampattavanich, Siwanon Jirawatnotai

    Published 2022-05-01
    Get full text
    Article

Search Tools: